Atara Biotherapeutics Inc at Barclays Global Healthcare Conference Transcript
Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech analysts at Barclays. It gives me a great pleasure to introduce Atara Biotherapeutics. With us today, we've got Pascal Touchon, the CEO of Atara.
Pascal, just maybe as an opening question before we get into Q&A. Perhaps you could give us a high-level introduction of the pipeline and the therapeutic focus and cash runway? Thank you.
Thank you, Peter, and good morning, good afternoon, everyone. It's a pleasure to talk to you today. Atara Biotherapeutics is a leading company in the field of allogeneic off-the-shelf T-cell immunotherapy. We are not only a very advanced platform, but we have 4 key strategic priorities, assets that are -- 2 of them in the clinic and 2 in late preclinical stage. Our most advanced asset, tab-cel or tabelecleucel, is right now in Phase III in relapsed/refractory PTLD, and we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
